Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...

Eli Lilly and Company (NYSE:LLY) generated $11.4 billion in revenue, reflecting a 20.5% year-over-year increase. The growth was primarily fueled by strong performances from Mounjaro and Zepbound ...

Eli Lilly and Company (NYSE:LLY) generated $11.4 billion in revenue, reflecting a 20.5% year-over-year increase. The growth was primarily fueled by strong performances from Mounjaro and Zepbound ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including ...

However, Eli Lilly paid its first dividend back in the 19th century. Eli Lilly's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss), are far from the only growth drivers in its ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.